Price$125.97-1.13 (-0.89%)
01:30 PM07:45 PM
News · 26 weeks151-54%
2026-01-112026-07-05
Mix8590d
- Insider42(49%)
- Other30(35%)
- SEC Filings9(11%)
- Earnings2(2%)
- Leadership1(1%)
- M&A1(1%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Seidman Christine E4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Karsanbhai Surendralal Lanca4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Coe Mary Ellen4 - Merck & Co., Inc. (0000310158) (Issuer)
- PRMerck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Aug. 4. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fre
- PRMerck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIVAgreement will help state ADAP programs provide access to IDVYNSO™ (doravirine/islatravir) for eligible individuals Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced an agreement with the ADAP Crisis Task Force (ACTF) to help state AIDS Drug Assistance Programs (ADAPs) provide access to the company’s new once-daily HIV treatment, IDVYNSO™ (doravirine/islatravir). In 2024, state ADAPs supported more than 250,000 people with HIV in the United States. IDVYNSO was approved by the U.S. Food and Drug Administration (FDA) in April 2026 as a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection
- PRFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)First approval of PD‑1 inhibitors in combination with a Trop-2-directed antibody-drug conjugate (ADC) in advanced TNBC, marking a potentially practice‑changing treatment option Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead’s Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Com
- SECSEC Form 11-K filed by Merck & Company Inc.11-K - Merck & Co., Inc. (0000310158) (Filer)
- SECSEC Form 11-K filed by Merck & Company Inc.11-K - Merck & Co., Inc. (0000310158) (Filer)
- SECSEC Form 11-K filed by Merck & Company Inc.11-K - Merck & Co., Inc. (0000310158) (Filer)
- PRThe Quest to Repair What Multiple Sclerosis Takes AwayAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (profile) is determin
- PRNext-Generation DNA Repair Inhibitors Could Capture Billions in Emerging MarketAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response ("DDR") inhibitors, a category of drugs that work by blocking cancer cells' capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase ("PARP") inhibitor that first defined the category. DDR-inhibiting therapies generated an estimated $7 billion-plus in worldwide sales in 2025, and the wider oncology, diagnostics and precision medicine markets are expected to approach about $750 billion by 2030. A fresh wave of inhibitor classes is now taking shape as the next major opportunity.
- PRU.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal DiseaseCAPVAXIVE is the only Pneumococcal Conjugate Vaccine (PCV) specifically indicated and studied in the U.S. for use in this population CAPVAXIVE, when added to existing primary pediatric pneumococcal vaccination series, helps deliver additional protection by including serotypes not contained in approved primary pediatric PCV series Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) to include children and adolescents aged 2 through 17 years who have completed a primary pediatric pneumococcal vaccination series a
- PRStudy Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All AgesEfficacy and safety are top preferences when selecting antipruritic treatments, but dog owners and veterinarians want options that are easier to administer, more affordable and improve compliance Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced results from a new global survey of dog owners and veterinarians revealing challenges and pain points associated with diagnosing the underlying cause of allergic skin disease in dogs and its treatment. According to Pet Owner and Vet Perspectives on Canine Pruritus: A Global Survey, about one-third of canine patients seen by U.S. ve
- PRMerck Animal Health to Acquire TARGANTARGAN's innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company's largest shareholders. The proposed acquisition is expected
- PRMerck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 StudyMerck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (NASDAQ:GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's Trodelvy® (sacituzumab govitecan-hziy) in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, compared to KEYTRUDA monotherapy in certain patients with previously untreated metastatic non-small cell lung cancer, whose tumors expressed PD-L1 (tumor proportion score [TPS] ≥50%). The decision is based on the recommendation from the external Data Monitoring Committee (eDMC) following their review of the data from the pre-specified final analysis of progression-free s
- PRApotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivityWESTON, Fla., June 3, 2026 /CNW/ - Apotex Corp. ("Apotex") today announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both of which are eligible for 180‑day shared exclusivity. These launches expand Apotex's portfolio of treatment options for adults living with type 2 diabetes mellitus. Type 2 diabetes affects millions of adults in the United States, and treatment often requires long-term, reliable access to prescribed therapies. Sitagliptin tablets are AB rated (per FDA's Approved Drug Products with Therapeutic Equivalence Evaluations) to JANUVIA® (Merck) and are indicated as a
- INSIDERSEC Form 4 filed by Director Warden Kathy J4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Karsanbhai Surendralal Lanca4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Coe Mary Ellen4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Thulin Inge G4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Seidman Christine E4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Russo Patricia F4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Rothman Paul4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Mayo Stephen4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Lavizzo-Mourey Risa J4 - Merck & Co., Inc. (0000310158) (Issuer)
MRK FAQ
7 questionsWhat does Merck & Company Inc. do?
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected...Where does MRK stock trade?
Merck & Company Inc. (MRK) is listed on NYSE.What sector and industry is MRK in?
Merck & Company Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does MRK pay a dividend?
MRK's most recent ex-dividend date was 2026-06-15 with a cash dividend of $0.85 per share. No future ex-date is on file yet.What are analysts saying about MRK?
Merck & Company Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Neutral on 2026-05-06.What companies are similar to MRK?
Notable peers in the same industry include AZN (AstraZeneca PLC), NVS (Novartis AG), AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), PFE (Pfizer Inc.). Compare MRK side-by-side with any of them on Quantisnow.How can I track MRK on Quantisnow?
Quantisnow aggregates Merck & Company Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MRK to receive live email and push alerts on every new disclosure.